1. Home
  2. PWUP vs MDXH Comparison

PWUP vs MDXH Comparison

Compare PWUP & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PWUP
  • MDXH
  • Stock Information
  • Founded
  • PWUP 2021
  • MDXH 2003
  • Country
  • PWUP United States
  • MDXH Belgium
  • Employees
  • PWUP N/A
  • MDXH N/A
  • Industry
  • PWUP Blank Checks
  • MDXH
  • Sector
  • PWUP Finance
  • MDXH
  • Exchange
  • PWUP Nasdaq
  • MDXH Nasdaq
  • Market Cap
  • PWUP 87.4M
  • MDXH 76.7M
  • IPO Year
  • PWUP 2022
  • MDXH 2021
  • Fundamental
  • Price
  • PWUP $11.25
  • MDXH $2.77
  • Analyst Decision
  • PWUP
  • MDXH Strong Buy
  • Analyst Count
  • PWUP 0
  • MDXH 2
  • Target Price
  • PWUP N/A
  • MDXH $7.50
  • AVG Volume (30 Days)
  • PWUP 233.0
  • MDXH 36.8K
  • Earning Date
  • PWUP 01-01-0001
  • MDXH 08-21-2024
  • Dividend Yield
  • PWUP N/A
  • MDXH N/A
  • EPS Growth
  • PWUP N/A
  • MDXH N/A
  • EPS
  • PWUP 0.18
  • MDXH N/A
  • Revenue
  • PWUP N/A
  • MDXH $75,327,000.00
  • Revenue This Year
  • PWUP N/A
  • MDXH $22.19
  • Revenue Next Year
  • PWUP N/A
  • MDXH $14.13
  • P/E Ratio
  • PWUP $62.50
  • MDXH N/A
  • Revenue Growth
  • PWUP N/A
  • MDXH 65.02
  • 52 Week Low
  • PWUP $10.07
  • MDXH $0.35
  • 52 Week High
  • PWUP $13.70
  • MDXH $4.64
  • Technical
  • Relative Strength Index (RSI)
  • PWUP 42.95
  • MDXH 55.73
  • Support Level
  • PWUP $11.26
  • MDXH $2.59
  • Resistance Level
  • PWUP $11.69
  • MDXH $2.98
  • Average True Range (ATR)
  • PWUP 0.00
  • MDXH 0.17
  • MACD
  • PWUP -0.00
  • MDXH 0.04
  • Stochastic Oscillator
  • PWUP 0.00
  • MDXH 71.78

About PWUP PowerUp Acquisition Corp.

PowerUp Acquisition Corp is a blank check company. It is formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses.

About MDXH MDxHealth SA

MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA), and Europe.

Share on Social Networks: